48,830
edits
Difference between revisions of "Muscularis propria invasion in the urinary bladder"
Jump to navigation
Jump to search
Muscularis propria invasion in the urinary bladder (view source)
Revision as of 15:35, 27 January 2017
, 15:35, 27 January 2017→IHC
(→IHC) |
|||
| (9 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[Image: Muscle invasive urothelial carcinoma -- intermed mag.jpg |thumb|350px|right | Muscle invasive urothelial carcinoma. [[H&E stain]].]] | |||
The presence or absence of '''muscularis propria invasion in the urinary bladder''' is a ''very important'' determination, as the clinical management changes between T1 and T2: | The presence or absence of '''muscularis propria invasion in the urinary bladder''' is a ''very important'' determination, as the clinical management changes between T1 and T2: | ||
*T1: usually conservative treatment (local excision). | *T1: usually conservative treatment (local excision). | ||
| Line 4: | Line 5: | ||
A thin layer of discontinous muscularis mucuosae (MM) is present and, especially if hypertrophic, may be confused with muscuaris propria (MP). | A thin layer of discontinous muscularis mucuosae (MM) is present and, especially if hypertrophic, may be confused with muscuaris propria (MP). | ||
Staging of bladder cancer is dealt with in the ''[[bladder cancer staging]]'' article. | |||
'''''Muscle invasive bladder cancer''''' redirects to this article and refers to invasion of the ''muscularis propria''. | |||
''Bladder muscularis propria invasion'' and ''urinary bladder muscularis propria invasion'' redirect to this article. | |||
==General== | ==General== | ||
| Line 53: | Line 60: | ||
#Multiple bundles must be adjacent to one another. | #Multiple bundles must be adjacent to one another. | ||
#Should '''not''' be superficial - surface epithelium if present should be distant. | #Should '''not''' be superficial - surface epithelium if present should be distant. | ||
DDx: | |||
*Invasion of hypertrophic muscularis mucosae. | |||
====Images==== | |||
<gallery> | |||
Image: Muscle invasive urothelial carcinoma -- very low mag.jpg | MIUC - very low mag. | |||
Image: Muscle invasive urothelial carcinoma -- low mag.jpg | MIUC - low mag. | |||
Image: Muscle invasive urothelial carcinoma - alt -- intermed mag.jpg | MIUC - intermed. mag. | |||
Image: Muscle invasive urothelial carcinoma -- high mag.jpg | MIUC - high mag. | |||
</gallery> | |||
==IHC== | |||
''Smoothelin'' [[immunostain]]:<ref name=pmid18936687>{{Cite journal | last1 = Paner | first1 = GP. | last2 = Shen | first2 = SS. | last3 = Lapetino | first3 = S. | last4 = Venkataraman | first4 = G. | last5 = Barkan | first5 = GA. | last6 = Quek | first6 = ML. | last7 = Ro | first7 = JY. | last8 = Amin | first8 = MB. | title = Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. | journal = Am J Surg Pathol | volume = 33 | issue = 1 | pages = 91-8 | month = Jan | year = 2009 | doi = 10.1097/PAS.0b013e3181804727 | PMID = 18936687 }}</ref> | |||
*Muscularis propria - usu. strong. † | |||
*Muscularis mucosae - negative/weak. † | |||
Note: | |||
*† Overlap between the patterns is described;<ref name=pmid20154589>{{Cite journal | last1 = Miyamoto | first1 = H. | last2 = Sharma | first2 = RB. | last3 = Illei | first3 = PB. | last4 = Epstein | first4 = JI. | title = Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma. | journal = Am J Surg Pathol | volume = 34 | issue = 3 | pages = 418-22 | month = Mar | year = 2010 | doi = 10.1097/PAS.0b013e3181ce5066 | PMID = 20154589 }}</ref> this limits the utility of the immunostain. | |||
**Immunostain '''not''' used in many practice environments. | |||
==Sign out== | ==Sign out== | ||
| Line 73: | Line 100: | ||
==See also== | ==See also== | ||
*[[Urothelial carcinoma]]. | *[[Urothelial carcinoma]]. | ||
*[[Bladder cancer staging]]. | |||
*[[Cancer staging systems]]. | *[[Cancer staging systems]]. | ||